Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) (NCT05986864)
Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Who can join: Review the eligibility criteria below.
Location: Retina Vitreous Associates of Florida - Saint Petersburg — St. Petersburg, Florida
Age range: 50 Years
🧪 Interventions in This Study
- SKG0106 (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Retina Vitreous Associates of Florida - Saint Petersburg — St. Petersburg, Florida
- Ophthalmic Consultants of Boston — Boston, Massachusetts
- Retina Consultants of Texas — Katy, Texas
- Wagner Kapoor Research Institute — Norfolk, Virginia
- The Second Hospital Of Anhui Medical University — Hefei, Anhui
- Zhejiang Provincial People's Hospital — Hangzhou, Zhejiang
- Eye Hospital, WMU (Zhejiang Eye Hospital) — Wenzhou, Zhejiang
- Beijing Hospital — Beijing,
- Peking Union Medical College Hospital — Beijing,
📞 Contact the Study Coordinator
Phone: (908) 884-1246
Email: eanglade@focusbiosciences.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neovascular Age-related Macular Degeneration
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) — Arcadia, California
- A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
- Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) — Beverly Hills, California
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Gilbert, Arizona
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD — Glendale, California
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] — Phoenix, Arizona
Explore by condition: All Neovascular Age-related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.